Tuesday, December 10, 2024 NIH Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution or Pain Colorized transmission electron micrograph of two particles of the virus that causes mpox, cultivated and purified from cell culture. Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID The antiviral drug tecovirimat did not improve mpox resolution or pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP). There were no safety concerns associated with tecovirimat. Further analyses and detailed results will be released through scientific channels. Learn More National Institute of Allergy and Infectious Diseases  |  National Institutes of Health

---

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period. 

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).

                           

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107